Is rituximab maintenance therapy after first-line induction chemoimmunotherapy for follicular lymphoma associated with improved outcomes?
Compared with observation, rituximab maintenance therapy prolongs progression-free survival without an improvement in overall survival or quality of life after first-line induction chemoimmunotherapy.
Hilal T, Leis JF, Reeder CB. Rituximab Maintenance Therapy After First-Line Induction Chemoimmunotherapy for Follicular Lymphoma. JAMA Oncol. 2018;4(6):859–860. doi:10.1001/jamaoncol.2018.0111
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: